Nuvectis Agrees to License Drug Assets from Haisco
Nuvectis Pharma expands its pipeline by licensing ex-China rights for NXP100 and NXP200 from Haisco Pharmaceutical Group. This strategic acquisition of two clinical-stage assets aims to strengthen the company's focus on complement-mediated diseases and oncology.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day